Sign in Subscribe
Cancer research

Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer

Strategic Insights

— 2 min read

Colon cancer remains a formidable global health challenge, with the majority of patients exhibiting microsatellite stable (MSS) and proficient mismatch repair (pMMR) tumors that are largely unresponsive to immune checkpoint inhibitors (ICIs). Researchers from Hubei Key Laboratory of Tumor Biological Behaviors have discussed new findings in colon cancer, highlighting the potential of combining cetuximab, an EGFR-targeting monoclonal antibody with immunomodulatory properties, with immunotherapy to enhance the immunotherapeutic response in MSS/pMMR CRC. This combination therapy may synergistically improve overall response rates and durability of response, but further large-scale, randomized, phase III clinical trials are required to confirm its efficacy and safety.

Key Takeaways:

  • The management of MSS/pMMR CRC remains a clinical challenge due to intrinsic resistance to ICIs.
  • Combining cetuximab with immunotherapy offers a promising strategy to enhance immunotherapeutic response in MSS/pMMR CRC.
  • The complementary therapeutic mechanisms of cetuximab and ICIs may synergistically improve overall response rates and durability of response.
  • Additional preclinical and clinical data are needed to confirm the efficacy and safety of cetuximab-ICI combinations.
  • Further large-scale, randomized, phase III clinical trials are required to confirm the efficacy and safety of this combination therapy.
  • The research concluded that combining cetuximab and immunotherapy for treating MSS/pMMR colorectal cancer is a promising strategy.
  • Bo Pei PhD, is a key researcher in this study, along with Shixuan Peng MS, Weiwei Chen BS, Lin Lai MS, and Fuxiang Zhou PhD.
  • The study was published in Technology in Cancer Research & Treatment, 2025,24.

Statistics:

  • The majority of CRC patients demonstrate MSS/pMMR tumors that are largely unresponsive to ICIs. (Source: NewsRx editors)
  • Combining cetuximab and immunotherapy may improve overall response rates and durability of response. (Source: Hubei Key Laboratory of Tumor Biological Behaviors)
  • The research concluded that cetuximab-ICI combinations are a promising strategy for treating MSS/pMMR CRC. (Source: NewsRx editors)
  • The ongoing clinical trials evaluating the safety and efficacy of cetuximab-ICI combinations are eagerly anticipated to pave the way for a new era in personalized immunotherapy for MSS/pMMR CRC. (Source: NewsRx editors)

Sources:

  • NewsRx. Researchers from Hubei Key Laboratory of Tumor Biological Behaviors Report on Findings in Colon Cancer (Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges). Cancer Weekly. May 20, 2025; p 404.
  • Hubei Key Laboratory of Tumor Biological Behaviors. Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges. Technology in Cancer Research & Treatment, 2025,24.
  • SAGE Publishing. Technology in Cancer Research & Treatment, 2025,24.

Read more